News
Current report No. 23/2022 – Registration of changes to the Company’s Articles of Association
Current report No. 23/2022 Date prepared: 09/14/2022 Abbreviated name of the issuer: CELON PHARMA S.A. Topic: Registration of changes to the Company’s Articles of Association Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: The Management Board of Celon Pharma S.A.Read more »
Current report No. 22/2022 – Decision of the Central Securities Depository of Poland (KDPW) on assimilation of 5,000 C share actions with the Company’s share in the stock exchange trading
Current report No. 22/2022Date prepared: 18/07/2022Abbreviated name of the issuer: CELON PHARMA S.A.Subject: Decision of the Central Securities Depository of Poland (KDPW) on assimilation of 5,000 C share actions with the Company’s share in the stock exchange tradingLegal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodicalRead more »
Current report 21/2022 – Admission and introduction of 5,000 ordinary C-series bearer shares of the Company to stock exchange trading
Current report No. 21/2022 Date prepared: 15/07/2022 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Admission and introduction of 5,000 ordinary C-series bearer shares of the Company to stock exchange trading Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report:Read more »
Current report No. 20/2022 – Summary of subscription of ordinary C-series bearer shares in Celon Pharma S.A. Performed under the 2021 Incentive Program
Current report No. 20/2022 Date prepared: 08/07/2022 Abbreviated name of the issuer: Celon Pharma S.A. Subject: Summary of subscription of ordinary C-series bearer shares in Celon Pharma S.A. performed under the Incentive Program for 2021 Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information ContentRead more »
Current report No. 19/2022 – Allocation of 5,000 C series shares under a conditional share capital increase.
Date prepared: 07/07/2022 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Allocation of 5,000 C series shares under a conditional share capital increase. Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: The Management Board of Celon Pharma S.A. (theRead more »
Current report No. 18/2022 – List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company held on June 22, 2022
Current report No. 18/2022 Date prepared: June 23, 2022 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company held on June 22, 2022 Legal basis subs. 70 point 3 of the Act on Public Offering – GeneralRead more »
Current report No. 17/2022 – Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2022
Date prepared: June 22, 2022 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: The Management Board of Celon Pharma S.A. (the “Company”) hereby publishes the text of the resolutions adopted by the Ordinary General Meeting of the Company on JuneRead more »
Current report No. 16/2022 – Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2021
Current report No. 16/2022Date prepared: June 22, 2022Abbreviated name of the issuer: CELON PHARMA S.A.Subject: Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2021Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodicalRead more »
Current report No. 15/2022 – Information on the status of the application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon’s esketamine DPI) in treatment-resistant bipolar depression therapy
Date: June 20, 2022, 7:42 AMLegal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. In relation to the current report No. 10/2022 of April 20, 2022 on the submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon’s esketamineRead more »
Current report No. 14/2022 – Supplementing the documentation for the Ordinary General Meeting of Celon Pharma S.A. convened to take place on June 22, 2022
Date prepared: June 15, 2022 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: As a supplement to current report No. 13/2022 dated May 26, 2022 announcing the Ordinary General Meeting of Celon Pharma S.A. convened to take place on JuneRead more »